Literature DB >> 10975233

The end of the line: has rapid transit contributed to the spatial diffusion of HIV in one of Canada's largest metropolitan areas?

E Wood1, K Chan, J S Montaner, M T Schechter, M Tyndall, M V O'Shaughnessy, R S Hogg.   

Abstract

The objective of this study is to describe the relationship between socio-demographic characteristics and the geographic distribution of persons with HIV in the metropolitan area surrounding Vancouver, British Columbia. Specifically, we sought to determine the location of persons with HIV and the population based characteristics related to the rate of anti-HIV medication use. In addition, we investigated the relationship between the distribution of persons on anti-HIV medications and the city's monorail "SkyTrain" route. The residences of persons on anti-HIV therapy were linked to Census Tracts. Data from the most recent census were used to create a socio-demographic profile of each geographic area. The spatial relationship between the distribution of persons on anti-HIV therapy and the path of the monorail was assessed by digitizing the SkyTrain route over a digital Census Tract map. Statistical analyses were used to determine the characteristics of Census Tracts associated with the rate of anti-HIV medication use. The overall rate of anti-HIV medication use in the Census Tracts that are within 1 km of SkyTrain was 66 per 100,000 population, whereas the rate was only 22 in the non-proximal Census Tracts. Multivariate analyses indicated that persons on anti-HIV therapy were significantly less likely to reside where there is a higher proportion of the population female, and were more likely to reside in areas with a higher proportion of the population of First Nations or Aboriginal descent, a higher population density, and in areas within 1 km of the SkyTrain route. Our analyses suggest that neither migration, nor a heightened access to therapy explain these findings. The environment surrounding the SkyTrain may have been conducive to the spatial diffusion of HIV, and could be the focus of targeted public health interventions. The mechanisms responsible for the clustering of persons on anti-HIV medications around the SkyTrain require further investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10975233     DOI: 10.1016/s0277-9536(99)00479-7

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  6 in total

1.  The geography of institutional psychiatric care in France 1800-2000: historical analysis of the spatial diffusion of specialised facilities for institutional care of mental illness.

Authors:  Magali Coldefy; Sarah E Curtis
Journal:  Soc Sci Med       Date:  2010-11-04       Impact factor: 4.634

2.  Are regions equal in adversity? A spatial analysis of spread and dynamics of COVID-19 in Europe.

Authors:  Mounir Amdaoud; Giuseppe Arcuri; Nadine Levratto
Journal:  Eur J Health Econ       Date:  2021-03-22

3.  Economic globalization and the COVID-19 pandemic: global spread and inequalities.

Authors:  Ludovic Jeanne; Sébastien Bourdin; Fabien Nadou; Gabriel Noiret
Journal:  GeoJournal       Date:  2022-03-11

4.  The Social Geography of Partner Selection in Toronto, Canada: A Qualitative Description of "Convection Mixing".

Authors:  Dionne Gesink; Travis Salway; Lauren Kimura; James Connell; Michael Widener; Olivier Ferlatte
Journal:  Arch Sex Behav       Date:  2019-10-18

5.  Virologic suppression and mortality of patients who migrate for HIV care in the province of British Columbia, Canada, from 2003 to 2012: a retrospective cohort study.

Authors:  Viviane Dias Lima; Nicola Goldberg; Lillian Lourenço; William Chau; Robert S Hogg; Silvia Guillemi; Rolando Barrios; Julio S G Montaner
Journal:  BMC Health Serv Res       Date:  2015-09-14       Impact factor: 2.655

6.  Spatial analysis of HIV positive injection drug users in San Francisco, 1987 to 2005.

Authors:  Alexis N Martinez; Lee R Mobley; Jennifer Lorvick; Scott P Novak; Andrea Lopez; Alex H Kral
Journal:  Int J Environ Res Public Health       Date:  2014-04-09       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.